Eric Sherman
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Sherman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04238624 · Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation · principal investigator
- Early Ph1NCT03085056 · Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Anaplastic Thyroid Cancer · principal investigator
- Ph2NCT02143726 · Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid CancerAlliance for Clinical Trials in Oncology · active not recruiting · Refractory Hurthle Cell Thyroid Cancer · study chair
- Ph2NCT01141309 · Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Thyroid Cancer · principal investigator
- Ph2NCT01025453 · Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid CancerMemorial Sloan Kettering Cancer Center · completed · Thyroid Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Instituting NCI-funded thyroid and head and neck cancer studiesR50CA305244 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2025 to 2026 · $201,870 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT02143726
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:45 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.J Clin Oncol · 2014683 citationsRCR 21.7
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.N Engl J Med · 2020647 citationsRCR 29.3
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.N Engl J Med · 2013643 citationsRCR 19.6
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.J Clin Oncol · 2008488 citationsRCR 12.2
- Transoral robotic surgery: radical tonsillectomy.Arch Otolaryngol Head Neck Surg · 2007455 citationsRCR 16.0
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.J Clin Oncol · 2021367 citationsRCR 19.3
- 311 citationsRCR 8.0
- 303 citationsRCR 9.6
- 295 citationsRCR 8.7
- Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.J Clin Oncol · 2019186 citationsRCR 8.5